viewImugene Ltd

Imugene reveals new data on cancer vaccine programs

Data shows combining KEY-Vaxx and B-Vaxx is more effective than KEY-Vaxx alone.

lecture theatre
KEY-Vaxx is a cancer vaccine designed to treat tumors such as lung cancer

Imugene Ltd (ASX:IMU) has welcomed new data being presented on its KEY-Vaxx and B-Vaxx cancer vaccine programs.

The data was presented by Dr Tanios Bekaii-Saabfrom the Mayo Clinic at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

The highlight and key finding of the KEY-Vaxx presentation demonstrated that KEY-Vaxx, when combined with B-Vaxx, is more effective in reducing tumor growth in a validated mouse model of colon carcinoma versus either the PD-1 KEY-Vaxx vaccine alone.

The vaccine combination was found to be safe and did not appear to exhibit toxicity or autoimmunity.

Imugene is working to evaluate KEY-Vaxx and its potential efficacy in a range of cancers.

New data from phase Ib study of HER-Vaxx

New data was also presented at the same event related to the phase Ib study of the HER-Vaxx cancer vaccine, in which 11 out of 14 evaluable patients showed clinically meaningful responses.

The phase 1b HER-Vaxx study reported no safety or toxicity issues and all evaluable patients showed increased antibody responses.

One patient saw a complete response, five had a partial response and four recorded a stabilisation of their disease.

Due to the success of the phase Ib trial, Imugene dosed its first patient in its phase II study in mid-March 2019.

Imugene’s managing director and CEO Leslie Chong said: “We are encouraged by the overall positive data from the phase Ib trial which clearly supports our B-cell platform cancer vaccine strategy for treating HER-2 positive gastric cancer.”

READ: Imugene gets development roadmap for cancer vaccine from FDA meeting

Recently, Imugene received minutes of its meeting with the (FDA) for its KEY-Vaxx cancer immunotherapy on 8 February 2019.

The meeting was aimed at seeking guidance on the studies required for phase I clinical development of KEY-Vaxx.

Quick facts: Imugene Ltd

Price: 0.032 AUD

Market: ASX
Market Cap: $115.68 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...



Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

23 hours, 49 minutes ago

2 min read